The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Prevalence of and Risk Factors for Medication Nonadherence in Patients With Schizophrenia: A Comprehensive Review of Recent Literature
Abstract
OBJECTIVE: Nonadherence to prescribed antipsychotic medications places patients with schizophrenia at a greatly increased risk of illness exacerbation and rehospitalization. Identification of risk factors for nonadherence is an initial step toward designing effective interventions. This article reviews recent literature on the prevalence of and risk factors for medication nonadherence in patients with schizophrenia. DATA SOURCES: We searched the MEDLINE/HealthSTAR and PsycINFO databases using combinations of the keywords risk factor(s), adherence, compliance, antipsychotic, neuroleptic, schizophrenia, and psychosis for articles published since 1980 that identified risk factors for medication nonadherence in schizophrenia patients. We included reports that (1) were published in English and (2) specifically examined risk factors for medication nonadherence. Thirty-nine articles met our selection criteria. DATA SYNTHESIS: Among the 10 reports that met a strict set of study inclusion criteria, we found a mean rate of nonadherence of 41.2%; the 5 reports that met a stricter set of inclusion criteria had a mean nonadherence rate of 49.5%. In the 39 articles reviewed, factors most consistently associated with nonadherence included poor insight, negative attitude or subjective response toward medication, previous nonadherence, substance abuse, shorter illness duration, inadequate discharge planning or aftercare environment, and poorer therapeutic alliance. Findings regarding an association between adherence and medication type were inconclusive, although few studies explored this relationship. Other factors such as age, gender, ethnicity, marital status, education level, neurocognitive impairment, severity of psychotic symptoms, severity of medication side effects, higher antipsychotic dose, presence of mood symptoms, route of medication administration, and family involvement were not found to be consistent predictors of nonadherence. Limitations of the published literature are discussed. CONCLUSION: Efforts to improve medication adherence in patients with schizophrenia should target relevant risk factors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Disruption of treatment coverage has been associated with symptom relapse and increased risk of hospitalization [5–7].”
From Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview (2021) · cites this paper as [6]
In the citing paper
“Similarly, medication non-adherence is consistently associated with patients behavioral practices (e.g., substance abuse) [14, 74] and also patients’ socio-demographic characteristics (such as educational status, age, gender, and employment) [14, 72].”
From Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis (2020) · cites this paper as [14]
In the citing paper
“In the present systematic review, medication non-adherence is associated with poor functioning of the health system such as lack of psychotherapy, lack of information, long treatment duration with little health personnel follow-up, inadequate discharge planning, increased hospitalizations, poor support and care environment, experiencing access barriers to high-quality care and health care”
From Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis (2020) · cites this paper as [14]
In the citing paper
“This systematic review of factors influencing psychotropic medication non-adherence which is consistent with other systematic reviews [14, 72, 73, 77] has shown that medication adherence is mainly affected by patients’ negative attitude toward their medication, lack of insight, negative health belief, and perceived stigma.”
From Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis (2020) · cites this paper as [14]
In the citing paper
“The present systematic review and meta-analysis finding is consistent with a finding from a comprehensive systematic review on schizophrenia which reported that a mean rate of non-adherence was 41.2%.”
From Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis (2020) · cites this paper as [14]
In the citing paper
“In addition, medication non-adherence is associated with clinical- or medication-related factors [14, 72–74, 77].”
From Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis (2020) · cites this paper as [14]
In the citing paper
“The sub-group analysis indicated that a mean non-adherence rate was 49.5% [14]”
From Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis (2020) · cites this paper as [14]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
The Health Belief Model: a decade later.
Janz, N. K., & Becker, M. H. (1984) · Health Education Quarterly · doi:10.1177/109019818401100101 · Cited by 8,437
Endicott, J. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770310043002 · Cited by 5,697
The Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance
Endicott, J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060086012 · Cited by 4,982
Negative Symptoms in Schizophrenia: Definition and Reliability
Andreasen, N. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290070020005 · Cited by 2,247
What is Motivational Interviewing?
Rollnick, S., & Miller, W. R. (1995) · Behavioural and Cognitive Psychotherapy · doi:10.1017/s135246580001643x · Cited by 1,737
Assessment of insight in psychosis
AMADOR, X. F., Strauss, D. H., Yale, S. A., FLAUM, M. M., Endicott, J., & Gorman, J. M. (1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.6.873 · Cited by 1,100
Hogan, T. P., Awad, A. G., & Eastwood, R. (1983) · Psychological Medicine · doi:10.1017/s0033291700050182 · Cited by 1,032
Cited by
Sorted by citations
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Determinants of patient adherence: a review of systematic reviews
Kardas, P., Lewek, P., & Matyjaszczyk, M. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00091 · Cited by 809
“…referral (Pampallona et al., 2002) Obtaining certification of preventive treatment (for immigrants to US) (Munro et al., 2007) Access to care (Lacro et al., 2002) Greater distance from the clinic (Jindal et al., 2003; Munro et al., 2007) Current inpatient status (Lacro et al., 2002) Rural…”
BackgroundInfluentialLysaker, P. H., Roe, D., & Yanos, P. T. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl016 · Cited by 688
Patient adherence to medical treatment: a review of reviews
van Dulmen, S., Sluijs, E., van Dijk, L., de Ridder, D., Heerdink, R., & Bensing, J. (2007) · BMC Health Services Research · doi:10.1186/1472-6963-7-55 · Cited by 627
“Overviews of the number of non-adherent patients can be found in various reviews [10-14].”
Psychoeducation for schizophrenia
Xia, J., Merinder, L. B., & Belgamwar, M. R. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002831.pub2 · Cited by 669
Tiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10081224 · Cited by 619
“2% of patients did not regularly take medication as prescribed (8), that prescription completion rates ranged from 28% to 85% (9), and that irregular medication use rates ranged from 31% to 62% (9).”
BackgroundGilmer, T. P., Dolder, C. R., Lacro, J. P., Folsom, D. P., Lindamer, L., Garcia, P., & Jeste, D. V. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.692 · Cited by 603
Self-citationBarnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 615
“…2002), presumably partly because a poorer therapeutic alliance has been consistently found to be associated with poor medication adherence (Lacro et al., 2002) and partly because environmental stress, particularly life events and high levels of expressed emotion within the family, are…”
BackgroundNonadherence with antipsychotic medication in schizophrenia: challenges and management strategies
Haddad, P. M., Brain, C., & Scott, J. L. (2014) · Patient Related Outcome Measures · doi:10.2147/prom.s42735 · Cited by 617
“The association between side effects and nonadherence is complex.(27,54) RCTs often report “dropouts” due to side effects or adverse effects, but individual perceptions or beliefs about the illness or the treatments are not recorded.”
Semahegn, A., Torpey, K., Manu, A., Assefa, N., Tesfaye, G., & Ankomah, A. (2020) · Systematic Reviews · doi:10.1186/s13643-020-1274-3 · Cited by 555
Leucht, S., Leucht, C., Huhn, M., Chaimani, A., Mavridis, D., Helfer, B., Samara, M., Rabaioli, M., Bächer, S., Cipriani, A., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16121358 · Cited by 542
Realistic expectations of prepulse inhibition in translational models for schizophrenia research
Swerdlow, N. R., Weber, M., Qu, Y., Light, G. A., & Braff, D. L. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1072-4 · Cited by 529
Kane, J. M., Kishimoto, T., & Correll, C. U. (2013) · World Psychiatry · doi:10.1002/wps.20060 · Cited by 520
“Lacro et al (17) reviewed the studies published between 1980 and 2000 which identified risk factors for medication non-adherence in patients with schizophrenia.”
BackgroundInfluentialCost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Dusetzina, S. B., Winn, A. N., Abel, G. A., Huskamp, H. A., & Keating, N. L. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.9123 · Cited by 501
“To do this, we assumed an unobserved variable exists, such as lack of understanding of one’s illness, associated with both type of health plan and/or level of copayment and adherence.(29,30) We then re-estimated the association of copayment level with the outcomes after adjusting for this unmeasured variable under spe…”
BackgroundNovick, D., Haro, J. M., Suarez, D. L., Pérez, V., Dittmann, R., & Haddad, P. M. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2009.05.004 · Cited by 446
“Coexisting alcohol dependence and substance abuse are common among patients with schizophrenia and, in agreement with previous studies (Owen et al., 1996; Kamali et al., 2001; Hunt et al., 2002; Lacro et al., 2002; Ascher-Svanum et al., 2006b), are associated with medication non-adherence.”
BackgroundResultSubstance Abuse and Psychiatric Disorders in HIV-Positive Patients
Chander, G., Himelhoch, S. S., & Moore, R. D. (2006) · Drugs · doi:10.2165/00003495-200666060-00004 · Cited by 376
Kishimoto, T., Hagi, K., Kurokawa, S., Kane, J. M., & Correll, C. U. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00039-0 · Cited by 369
Adherence to Antipsychotic Medication in Bipolar Disorder and Schizophrenic Patients
García, S., Martínez‐Cengotitabengoa, M., López-Zurbano, S., Zorrilla, E. P., López‐Mahía, P., Vieta, E., & González-Pinto, A. M. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000523 · Cited by 363
“Regarding modifiable factors, a psychological model has been proposed, the Health Belief Model, which aims to explain and predict health behaviors, focusing on attitudes and beliefs of individuals that may have an influence on adherence.(16) This model indicates 2 behaviors that play a very important role in medicatio…”
Barnes, T. R. E. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 369
“…and aversive subjective side effects, is particularly important at this stage given that they can be a short-term disincentive for medication adherence and have an impact on attitudes to drug treatment and mental health care over the longer term (Perkins et al., 2008; Robinson et al., 2002).”
BackgroundMethodHow often do patients with psychosis fail to adhere to treatment programmes? A systematic review
Nosè, M., Barbui, C., & Tansella, M. (2003) · Psychological Medicine · doi:10.1017/s0033291703008328 · Cited by 353
“This finding was lower than figures quoted in other studies (Fenton et al. 1997; Cramer &Rosenheck, 1998; Kampaman & Lehtine, 1999; Oehl et al. 2000; Lacro et al. 2002).”
ResultDiBonaventura, M., Gabriel, S., Dupclay, L., Gupta, S., & Kim, E. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-20 · Cited by 333
“Prior evidence has suggested that longer illness duration is associated with greater adherence [30]; therefore, age may be serving as a proxy for years diagnosed.”
BackgroundFalkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Möller, H., & WFSBP Task Force on Treatment Guide (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970500483177 · Cited by 330
Velligan, D. I., Sajatovic, M., Hatch, A., Kramata, P., & Docherty, J. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s124658 · Cited by 333
“Thirteen studies analyzed the relationship between substance abuse and adherence: 6 were prospective, 7 were cross-sectional, and all demonstrated a significant association.”
Medication Adherence: A Review of the Literature and Implications for Clinical Practice
Julius, R. J., Novitsky, M. A., & Dubin, W. R. (2009) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000344917.43780.77 · Cited by 301
Hallucinations: The science of idiosyncratic perception.
Aleman, A., & Larøi, F. (2008) · American Psychological Association eBooks · doi:10.1037/11751-000 · Cited by 291
Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Möller, H., & WFSBP Task Force on Treatment Guide (2005) · The World Journal of Biological Psychiatry · doi:10.1080/15622970510030090 · Cited by 271
“…antipsychotic treatment, unemployment, homelessness, violence, incarceration, suicide and HIV infection (e.g., Mueser et al. 1990; Olivera et al. 1990; Soyka et al. 1993; Linszen et al. 1994; Blanchard et al. 2000; Mueser et al. 2000; Goldham et al. 2002; Hunt et al. 2002; Lacro et al. 2002).”
BackgroundLambert, M., Conus, P., Eide, P., Mass, R., Karow, A., Moritz, S., Golks, D., & Naber, D. (2004) · European Psychiatry · doi:10.1016/j.eurpsy.2004.06.031 · Cited by 268
“[30] cite several factors that have been variously linked with adherence to medication.”
BackgroundResultWhat’s in a name? Compliance, adherence and concordance in chronic psychiatric disorders
Chakrabarti, S. (2014) · World Journal of Psychiatry · doi:10.5498/wjp.v4.i2.30 · Cited by 257
Paliperidone for schizophrenia
Dolder, C. R., Nelson, M., & Deyo, Z. M. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070261 · Cited by 252
Self-citationMorrison, A. P., Turkington, D., Pyle, M., Spencer, H. M., Brabban, A., Dunn, G., Christodoulides, T., Dudley, R. E. J., Chapman, N., Callcott, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62246-1 · Cited by 265
Sendt, K.-V., Tracy, D. K., & Bhattacharyya, S. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2014.11.002 · Cited by 245
“Interestingly, even antipsychotic-induced side effects do not appear to reliably predict whether patients continue taking medication as prescribed (Lacro et al., 2002; Robinson et al., 2002; Fleischhacker et al., 2003; Marder, 2003; Perkins et al., 2008).”
BackgroundResultInfluentialKaul, I., Sawchak, S. T., Correll, C. U., Kakar, R., Breier, A. F., Zhu, H., Miller, A., Paul, S. M., & Brannan, S. K. (2023) · The Lancet · doi:10.1016/s0140-6736(23)02190-6 · Cited by 255
Interventions to Improve Antipsychotic Medication Adherence: Review of Recent Literature
Dolder, C. R., Lacro, J. P., Leckband, S. G., & Jeste, D. V. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000085413.08426.41 · Cited by 236
“Modifiable factors consistently associated with nonadherence to antipsychotic medications should be considered targets for interventions.(5,6) In this paper, we review the interventions used to enhance antipsychotic adherence in chronic schizophrenia patients.”
BackgroundSelf-citationByerly, M., Nakonezny, P. A., & Rush, A. J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.12.470 · Cited by 229
“The b70% EM adherence cutoff was selected because it was both conservative in detecting nonadherence and consistent with definitions from prior published research (Lacro et al., 2002).”
Staring, A. B. P., van der Gaag, M., van der Gaag, M., Hj, D., & Mulder, C. L. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.06.015 · Cited by 241
“…insight into illness is associatedwith fewer symptoms, better psychosocial functioning, and better compliance with antipsychotic medication (Francis and Penn, 2001; Kozuki et al., 2005; Lacro et al. 2002; Lysaker et al., 1998, 2002; Mohamed et al., 2009; Perkins 2002; Rittmannsberger et al. 2004).”
Tolerability and adherence issues in antidepressant therapy
Masand, P. S. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80220-5 · Cited by 215
Medication adherence in schizophrenia
Acosta, F. J. (2012) · World Journal of Psychiatry · doi:10.5498/wjp.v2.i5.74 · Cited by 215
Lecomte, T., Spidel, A. L., LECLERC, C., MacEwan, G. W., GREAVES, C., & Bentall, R. P. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.01.024 · Cited by 212
“Other results such as the fact that more men and more individuals who had had trouble with the law did not adhere to medication or had poor engagement, have been found in other studies, though not systematically (Lacro et al., 2002).”
ResultCorrell, C. U., Kim, E., Sliwa, J. K., Hamm, W., Gopal, S., Mathews, M., Venkatasubramanian, R., & Saklad, S. R. (2021) · CNS Drugs · doi:10.1007/s40263-020-00779-5 · Cited by 205
Carroll, C. L., Feldman, S. R., CAMACHO, F. T., Manuel, J. C., & Balkrishnan, R. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.01.052 · Cited by 195
Adherence therapy for people with schizophrenia
Gray, R. J., Leese, M., Bindman, J. P., Becker, T. M., Burti, L., David, A. S., Gournay, K., Kikkert, M., Koeter, M. W. J., Puschner, B., et al. (2006) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.105.019489 · Cited by 194
Llorca, P. M., Abbar, M., Courtet, P., Guillaume, S., Lancrenon, S., & Samalin, L. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-340 · Cited by 188
“For example, the majority of patients with schizophrenia (84%) discontinue their index antipsychotic during the follow-up period [2] and in the long-term perspective, 40 to 50% seem to be noncompliant [3], with no real difference in terms of adherence between first-generation antipsychotics (FGA) and second-generation…”
BackgroundConley, R. R., Gupta, S., & Sathyan, G. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x132613 · Cited by 187
CLINICAL PRACTICE GUIDELINES Treatment of Schizophrenia
Paris, J., Bland, R. C., Goldbloom, D. S., Grof, P., LESAGE, A. D., Streiner, D. L., Addington, D. E., Arboleda‐Flórez, J., Benkelfat, C., Bond, M., et al. (2005) · Cited by 184
Barkhof, E., Meijer, C. J., de Sonneville, L. M. J., Linszen, D. H., & de Haan, L. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.02.005 · Cited by 183
“Also, general beliefs and attitudes towards health and taking medication, based on previous experiences, cultural factors and socioeconomic status, are associated with adherence [56].”
BackgroundResultInfluentialJeste, S., Patterson, T. L., Palmer, B. W., Dolder, C. R., Goldman, S., & Jeste, D. V. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00314-6 · Cited by 183
Self-citationByerly, M., Fisher, R., Whatley, K., Holland, R., Varghese, F. P., Carmody, T. J., Magouirk, B., & Rush, A. J. (2005) · Psychiatry Research · doi:10.1016/j.psychres.2004.11.002 · Cited by 181
“Thus, we chose to reduce the most conservative definition of non-adherence reported in a recent extensive review of antipsychotic non-adherence in schizophrenia (a threshold of V75% of prescribed antipsychotic) (Lacro et al., 2002).”
MethodAntipsychotic Medication Adherence in Schizophrenia
Byerly, M., Nakonezny, P. A., & Lescouflair, E. (2007) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2007.04.002 · Cited by 177
Lack of Insight in Schizophrenia
Buckley, P. F., Wirshing, D. A., Bhushan, P., Pierre, J. M., Resnick, S. A., & Wirshing, W. C. (2007) · CNS Drugs · doi:10.2165/00023210-200721020-00004 · Cited by 176
Duration of Adjuvant Chemotherapy for Colon Cancer and Survival Among the Elderly
Neugut, A. I., Matasar, M. J., Wang, X., McBride, R. B., Jacobson, J. S., Tsai, W., Grann, V. R., & Hershman, D. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5005 · Cited by 171
Rief, W., Avorn, J., & Barsky, A. J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.2.155 · Cited by 167
“Compared with clinical practice, clinical trials might include patients with higher motivation to tolerate adverse effects and with more optimistic drug attitudes; these patients are likely to report fewer adverse effects and discontinue use of medication less frequently than patients in clinical practice.(52)”
Medication Adherence in Schizophrenia: Exploring Patients', Carers' and Professionals' Views
Kikkert, M. J., Schene, A. H., Koeter, M. W. J., Robson, D., Born, A., Helm, H., Nose, M., Goss, C., Thornicroft, G., & Gray, R. J. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl011 · Cited by 164
Pan, P., Lee, M., & Yeh, C. (2015) · BMC Psychiatry · doi:10.1186/s12888-014-0378-5 · Cited by 159
“However, it is common for patients with schizophrenia to have low adherence to antipsychotics [8-10] and it had been reported that almost half of schizophrenic patients took less than 70% of the expected prescribed doses [11].”
BackgroundMedication nonadherence: health impact, prevalence, correlates and interventions
Stewart, S.-J., Moon, Z., & Horne, R. (2022) · Psychology and Health · doi:10.1080/08870446.2022.2144923 · Cited by 204
“…of a medicine in terms of symptom relief is related to adherence (Costello et al., 2008; Croome et al., 2017; Kardas et al., 2013; Munro et al., 2007; van der laan et al., 2017; Weiner et al., 2008), but this is not consistent across studies (lacro et al., 2002; olthoff et al., 2005).”
BackgroundResultMojtabai, R., Fochtmann, L. J., Chang, S.-W., Kotov, R., Craig, T., & Bromet, E. J. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp045 · Cited by 167
“A large number of clinical studies have specifically examined the impact of clinical and sociodemographic characteristics on treatment patterns in general and on adherence with medication treatments in particular.(68,69)”
BackgroundLiu‐Seifert, H., Adams, D. H., & Kinon, B. J. (2005) · BMC Medicine · doi:10.1186/1741-7015-3-21 · Cited by 154
Predictors of medication adherence in patients with schizophrenia and bipolar disorder
Jónsdóttir, H., Opjordsmoen, S., Birkenaes, A. B., Simonsen, C., Engh, J. A., Ringen, P. A., Vaskinn, A., Friis, S., Sundet, K. S., & Andreassen, O. A. (2012) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2012.01911.x · Cited by 158
“This finding is in line with earlier results in schizophrenia (7), even though some have found an association between lower adherence and psychotic symptoms (77), or depressive symptoms (34).”
BackgroundMethodResultInfluentialBrain delivery of olanzapine by intranasal administration of transfersomal vesicles
Ha, S., Mahmoud, A. A. K., Kamel, A. O., Hady, M. A., & Awad, G. A. S. (2012) · Journal of Liposome Research · doi:10.3109/08982104.2012.700460 · Cited by 151
“Olanzapine has five times the affinity for 5-HT2 receptors than for D2 receptors, resulting in fewer extrapyramidal side effects (Lacro et al., 2002) and minimal perturbation of prolactin levels (Callaghan et al., 1999).”
BackgroundMasand, P. S., Roca, M., Turner, M. S., & Kane, J. M. (2009) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.08r00612 · Cited by 151
“Based on a review of 39 studies, however, Lacro et al.(24) found no association between adherence and either age or gender.”
MethodSeale, C. F., Chaplin, R., Lelliott, P. T., & Quirk, A. (2005) · Social Science & Medicine · doi:10.1016/j.socscimed.2005.11.002 · Cited by 148
Clinical guideline recommendations for antipsychotic long-acting injections
Kane, J. M., & García-Ribera, C. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.195.52.s63 · Cited by 147
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Thibaut, F., Möller, H., & on behalf of the WFSBP Task Force on Treatment Guidelines for Schizophrenia (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2015.1009163 · Cited by 147
“…non-complicance, elevated rates of motor side-effects in general and during antipsychotic treatment, unemployment, homelessness, violence, incarceration, suicide and HIV infection (Mueser et al. 1990; Soyka et al. 1993; Drake et al. 2001; Hunt et al. 2002; Lacro et al. 2002; Wobrock et al. 2008).”
BackgroundOlivares, J. M., Rodriguez-Morales, A., Diels, J., Povey, M., Jacobs, A., Zhao, Z., & Lam, A. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2008.12.002 · Cited by 141
“A number of studies have associated low patient insight with poor medication compliance [19,20].”
BackgroundMontes, J. M. G., Medina, E., Gómez-Beneyto, M., & Mauriño, J. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.07.034 · Cited by 140
“Some known factors consistently associated with a lack of adherence were found to be associated with a lesser improvement with the intervention: larger numbers of hospitalisations, previous need for hospitalisation or worse previous adherence (Lacro et al., 2002).”
BackgroundSelf-disorders and Schizophrenia: A Phenomenological Reappraisal of Poor Insight and Noncompliance
Henriksen, M. G., & Parnas, J. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt087 · Cited by 154
Yang, J.-W., Ko, Y., Paik, J., Lee, M., Han, C., Joe, S.-H., Jung, I., Jung, H.-G., & Kim, S. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.11.008 · Cited by 138
“Lacro et al. (2002) reported that age, gender, marital status, education, neurocognitive impairment, dose of medication, or mood symptoms were not associated with non-adherence.”
InfluentialInsight and medication adherence in schizophrenia: An analysis of the CATIE trial
Kim, J., Ozzoude, M., Nakajima, S., Shah, P., Caravaggio, F., Iwata, Y., Luca, V. D., Graff‐Guerrero, A., & Gerretsen, P. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.011 · Cited by 144
The Therapeutic Relationship and Adherence to Antipsychotic Medication in Schizophrenia
McCabe, R., Bullenkamp, J., Hansson, L. I., Lauber, C., Martínez‐Leal, R., Wulf Rössler, A., Salize, H. J., Svensson, B., Torres‐González, F., van den Brink, R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036080 · Cited by 143
Medication adherence and its determinants in patients after myocardial infarction
Pietrzykowski, Ł., Michalski, P., Kosobucka, A., Kasprzak, M., Fabiszak, T., Stolarek, W., Siller-Matula, J. M., & Kubica, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-68915-1 · Cited by 136
Byerly, M., Thompson, A. K., Carmody, T. J., Bugno, R., Erwin, T., Kashner, M. T., & Rush, A. J. (2007) · Psychiatric Services · doi:10.1176/ps.2007.58.6.844 · Cited by 134
Tsang, H. W. H., Ching, S., Tang, K. H., Lam, H., Law, P. Y. Y., & Wan, C. N. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.02.013 · Cited by 145
“Unfortunately, poorer treatment adherence was related to poorer treatment outcomes, more re-hospitalization, and increased health costs (Lacro et al., 2002).”
BackgroundNon-adherence with psychotropic medications in the general population
Bulloch, A. G. M., & Patten, S. B. (2009) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-009-0041-5 · Cited by 133
Relating Therapy for distressing auditory hallucinations: A pilot randomized controlled trial
Hayward, M., Jones, A.-M., Bogen-Johnston, L., Thomas, N., & Strauss, C. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2016.11.019 · Cited by 128
“Despite evidence for its benefits, antipsychotic medication is often not fully effective, and 40–50% of patients are nonadherent (Lacro et al., 2002).”
Beck, E., Cavelti, M., Kvrgic, S., Kleim, B., & Vauth, R. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.07.019 · Cited by 131
“However, it seems to be the rule rather than the exception (Lacro et al., 2002; Nose et al., 2003; Velligan et al., 2010).”
Medication Adherence in Outpatients With Severe Mental Disorders
Jónsdóttir, H., Opjordsmoen, S., Birkenaes, A. B., Engh, J. A., Ringen, P. A., Vaskinn, A., Aamo, T. O., Friis, S., & Andreassen, O. A. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181d2191e · Cited by 126
“Rates of nonadherence to antipsychotics in schizophrenia patients have been reported in the range from 11% to 89%,(4,5) and a recent review found a mean rate of 41% (range, 20%Y56%).(6) In bipolar disorder, adherence to long-term prophylactic pharmacotherapy ranges from 20% to 66%,(7) and the importance of improving a…”
BackgroundResultRelational Agents in Clinical Psychiatry
Bickmore, T., & Gruber, A. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673221003707538 · Cited by 112
Acosta, F. J., Bosch, E., Sarmiento, G., Juanes, N., Caballero-Hidalgo, A., & Mayans, T. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.09.007 · Cited by 119
“To date, the main risk factors for noncompliance include: previous noncompliance (Lacro et al., 2002; Ascher-Svanum et al., 2006), poor insight, negative attitudes or subjective responses to medication, substance abuse and poor therapeutic alliance (Lacro et al.”
BackgroundResultInfluentialJónsdóttir, H., Friis, S., Horne, R., Pettersen, K. I., Reikvam, A., & Andreassen, O. A. (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01279.x · Cited by 118
“Adherence has been related to a range of factors, among them insight into illness and into symptoms (2, 3, 5, 22).”
BackgroundMoreno-Pino, F., Porras-Segovia, A., López-Esteban, P., Artés, A., & Baca-García, E. (2019) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.8032 · Cited by 112
Emotional dysfunction in schizophrenia spectrum psychosis: the role of illness perceptions
WATSON, P. W. B., Garety, P. A., Weinman, J. A., Dunn, G., Bebbington, P., Fowler, D. G., Freeman, D. H., & Kuipers, E. (2006) · Psychological Medicine · doi:10.1017/s0033291706007458 · Cited by 120
“Although much research has sought factors predictive of adherence-related behaviour (Pan & Tantam, 1989; Kampmann & Lehtinen, 1999; Lacro et al. 2002), and compliance therapy has been effective in improving medication adherence (Kemp et al.”
BackgroundMental illness stigma: Types, constructs, and vehicles for change.
Corrigan, P. W., & Kosyluk, K. A. (2013) · American Psychological Association eBooks · doi:10.1037/14297-003 · Cited by 115
Remission in Schizophrenia: Critical and Systematic Review
AlAqeel, B., & Margolese, H. C. (2012) · Harvard Review of Psychiatry · doi:10.3109/10673229.2012.747804 · Cited by 123
Czobor, P., Van Dorn, R. A., Citrome, L., Kahn, R. S., Fleischhacker, W. W., & Volavka, J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.04.003 · Cited by 112
“The other eight studies demonstrated little or no association (Lacro et al., 2002).”
BackgroundResultDassa, D., Boyer, L., Benoît, M., Bourcet, S., Raymondet, P., & Bottaï, T. (2010) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048674.2010.493503 · Cited by 111
Ascher‐Svanum, H., Zhu, B., Faries, D. E., Landbloom, R. P., Swartz, M. S., & Swanson, J. W. (2006) · BMC Psychiatry · doi:10.1186/1471-244x-6-8 · Cited by 112
“Most of these socio-demographic and treatment variables have been previously reported to be related to nonadherence with antipsychotic medication in the treatment of schizophrenia [25].”
BackgroundMiller, R., Ream, G. L., McCormack, J., Gunduz‐Bruce, H., Sevy, S. M., & Robinson, D. G. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.04.018 · Cited by 110
“, our adherence findings are consistent with other studies of substance abuse and adherence for people with schizophrenia (Lacro et al., 2002) and first-episode psychosis (Coldham et al.”
InfluentialHarrison, T. S., & Goa, K. L. (2004) · CNS Drugs · doi:10.2165/00023210-200418020-00005 · Cited by 109
A Review of Virtual Week for Prospective Memory Assessment: Clinical Implications
Rendell, P. G., & Henry, J. D. (2009) · Brain Impairment · doi:10.1375/brim.10.1.14 · Cited by 109
Tandon, R., Marcus, R. N., Stock, E. G., Riera, L. C., Kostic, D., Pans, M., McQuade, R. D., Nyilas, M., Iwamoto, T., & CRANDALL, D. T. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2005.12.857 · Cited by 107
“This finding is relevant in the context of relatively poor adherence to antipsychotic medications and the increased risk for relapse after treatment discontinuation (Hudson et al., 2004; Keith and Kane, 2003; Lacro et al., 2002).”
BackgroundEffects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine
Castberg, I., Westin, A. A., Skogvoll, E., & Spigset, O. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12794 · Cited by 107
“In a few studies, females have been found to have higher adherence than males (35, 36), but in most studies, no gender effects have been revealed (37).”
BackgroundSubjective well‐being under neuroleptic treatment and its relevance for compliance
Набер, Д., Karow, A., & Lambert, M. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2005.00542.x · Cited by 107
Adherence to pharmacotherapy in patients with alcohol and opioid dependence
Weiss, R. D. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00884.x · Cited by 107
Medication Adherence Among Psychotic Patients Before Admission to Inpatient Treatment
Rittmannsberger, H., Pachinger, T., Keppelmüller, P., & Wancata, J. (2004) · Psychiatric Services · doi:10.1176/appi.ps.55.2.174 · Cited by 105
Factors associated with relapse in schizophrenia
Kazadi, N. J.-B., Moosa, M. Y. H., & Jeenah, F. Y. (2008) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v14i2.158 · Cited by 103
Eticha, T., Teklu, A., Ali, D., Solomon, G., & Alemayehu, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120560 · Cited by 103
“A comprehensive review [3] reported that the rate of medication non-adherence in patients with schizophrenia is as high as 40%–50%.”
BackgroundJavadpour, A., Hedayati, A., Dehbozorgi, G., & Azizi, A. (2013) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2012.12.005 · Cited by 102
“On the other hand, as reported by Lacro et al. (2002), it is known that the rate of individual bipolar patients routinely and consciously taking the prescribed medicines is only 35%, which is much lower than that of schizophrenics at 50–60%.”
BackgroundThe relationship between patient satisfaction and treatment outcomes in schizophrenia
Chue, P. S. (2006) · Journal of Psychopharmacology · doi:10.1177/1359786806071246 · Cited by 102
Early Predictors of Nonadherence to Antipsychotic Therapy in First-Episode Psychosis
Rabinovitch, M., Béchard‐Evans, L., Schmitz, N., Joober, R., & MALLA, A. K. (2009) · The Canadian Journal of Psychiatry · doi:10.1177/070674370905400106 · Cited by 99
“We failed to observe previously reported association between adherence and insight into illness(1,3,12,21) and (or) a history of current or past substance use disorder.(1,12) Our measure of insight based on one item on the PANSS may be too limited to detect differences for the various domains of insight.”
ResultBhanji, N. H., Chouinard, G., & Margolese, H. C. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(03)00109-3 · Cited by 99
“A substantial literature exists on issues relating to compliance in schizophrenia, and has been summarized in recent reviews (Kane and Nemec, 2002; Lacro et al., 2002; Donohoe et al., 2001; Hellewell, 2002; Misdrahi et al., 2002).”
BackgroundPilon, D., Tandon, N., Lafeuille, M., Kamstra, R. L., Émond, B., Lefèbvre, P., & Joshi, K. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.08.008 · Cited by 98
“Similarly, a previously published systematic review found mean adherence rates of 51% and 59% depending on the inclusion criteria used.(11) The lower adherence that was observed in our analysis likely stems from the longer observation period used (12 months vs 6 months used by Marcus et al).”
BackgroundResult
Metadata
- Authors
- Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V.
- Affiliations
- University of California San Diego (US)
- VA San Diego Healthcare System (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2002-10-15
- Volume
- 63
- Issue
- 10
- Pages
- 892-909
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2070893229
- Cited by
- 1,383
- References
- 74
- Citations by year
- 2026: 42 · 2025: 29 · 2024: 43 · 2023: 55 · 2022: 59 · 2021: 58 · 2020: 63 · 2019: 52 · 2018: 56 · 2017: 65 · 2016: 80 · 2015: 74 · 2014: 57 · 2013: 103 · 2012: 97
- FWCI
- 18.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r29mh056938-04)
- National Institute of Mental Health (MH49671, R01MH059101, MH-43693, MH56938, MH59101, P30MH049671, MH-19934, T32MH019934)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- medication non-adherence, schizophrenia, antipsychotic drugs, risk factors, prevalence, lack of insight, substance abuse, therapeutic relationship, aftercare planning, hospital readmission
- MeSH terms
- Adult, Ambulatory Care, Factor Analysis, Statistical, Female, Hospitalization, Humans, Male, Probability, Research Design, Risk Factors, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Prevalence, Treatment Refusal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
